Related Experiment Videos
[Addition of beta blockers in chronic heart failure]
L H Missault1, D J van Veldhuisen
1St. Jan Ziekenhuis, afd. Cardiologie, Brugge, België. luc.missault@azbrugge.be
Insights
Adding beta-blockers to standard treatment significantly reduces mortality and hospitalizations in chronic heart failure patients. Careful initiation with low doses in stabilized patients is crucial for optimal outcomes.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Chronic heart failure (CHF) is a growing cause of hospitalization in the Netherlands and Belgium.
- High mortality rates persist despite existing medical treatments for CHF.
Purpose:
- To evaluate the impact of adding beta-blockers to established treatments for chronic heart failure.
- To assess changes in mortality and hospitalization frequency in CHF patients receiving beta-blockers.
Summary:
- Recent randomized trials indicate that beta-blockers, when added to angiotensin-converting enzyme (ACE) inhibitors, diuretics, and digitalis in stabilized CHF patients, decrease mortality by approximately 5% absolutely and 35% relatively.
- Beta-blocker therapy also leads to a reduction in hospitalization frequency.
- Initial benefits may be subtle, and careful dose titration starting with low doses in stable patients is recommended, with gradual increases every 2-4 weeks.
Impact:
- Beta-blocker addition offers a significant survival benefit and reduces healthcare utilization in specific chronic heart failure populations.
- Findings underscore the importance of cautious initiation and dose management for beta-blockers in CHF.
- Results from clinical trials may not be directly generalizable to all CHF patients encountered in routine practice.
Abstract:
Chronic heart failure is an increasing cause of hospital admission in the Netherlands and Belgium. Despite numerous medical treatment modalities, the mortality remains high. Recent placebo-controlled randomized studies suggest that the addition of beta-blockers in stabilized, optimally pretreated patients with chronic heart failure using angiotensin converting enzyme (ACE) inhibitors, diuretics and digitalis, is accompanied by an additional absolute decrease in mortality by about 5% and a relative decrease in mortality by about 35%. Also the number hospitalization frequency decreases. Initially, the beneficial effects of beta-blockers on symptoms are only minor or absent. During the initiation period some clinical deterioration may occur which has to be treated accordingly; these patients are, however, difficult to identify. Initiation has to be done using low doses and should be restricted to stabilized, optimally treated patients. Doses should only be increased every 2 to 4 weeks until target doses are reached. These findings must not be extrapolated automatically to all cases of heart failure, since patients in the trials may differ considerably from those encountered in general practice.